
Sign up to save your podcasts
Or


Antibody-drug conjugates (ADCs) are new chemotherapeutic agents that can cause significant ocular side effects. Drs. Meghan Berkenstock, Lauren Dalvin, and Stella Kim review this new class of drugs and how they can affect the eye, providing essential tips for what to look for, when to screen, and how to treat the side effects. Prescribing information mentioned in this episode: Elahere (mirvetuximab soravtansine-gynx) Tivdak (tisotumab vedotin-tftv)
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.
By American Academy of Ophthalmology4.9
5050 ratings
Antibody-drug conjugates (ADCs) are new chemotherapeutic agents that can cause significant ocular side effects. Drs. Meghan Berkenstock, Lauren Dalvin, and Stella Kim review this new class of drugs and how they can affect the eye, providing essential tips for what to look for, when to screen, and how to treat the side effects. Prescribing information mentioned in this episode: Elahere (mirvetuximab soravtansine-gynx) Tivdak (tisotumab vedotin-tftv)
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

43 Listeners

17 Listeners

5 Listeners

276 Listeners

8 Listeners

10 Listeners

21 Listeners

10 Listeners

10 Listeners

16 Listeners

18 Listeners

0 Listeners

1 Listeners

17 Listeners

3 Listeners